Factors contributing to the inhibition of HIV reverse transcriptase by chain-terminating nucleotides in vitro and in vivo
- PMID: 1718777
- DOI: 10.1016/0014-5793(91)81089-q
Factors contributing to the inhibition of HIV reverse transcriptase by chain-terminating nucleotides in vitro and in vivo
Abstract
Arguments are presented leading to the conclusion that two major factors contribute to the potency of inhibition of DNA-polymerase activity by chain-terminating nucleotides. The relative significance of these factors varies with the reaction conditions, particularly with the length of the template and the concentration ratio of enzyme (reverse transcriptase or other DNA polymerase) to primer. It is concluded that potent inhibition of HIV-reverse transcriptase activity under typical in vitro and in vivo conditions arises from different features of the interaction of chain terminators with the enzyme. A new method of testing for the parameter important under in vivo conditions is suggested.
Similar articles
-
Synergistic inhibition of HIV-1 reverse transcriptase by combinations of chain-terminating nucleotides.Biochemistry. 1997 Oct 28;36(43):13223-31. doi: 10.1021/bi970852k. Biochemistry. 1997. PMID: 9341211
-
Sensitivity of HIV-1 reverse transcriptase and its mutants to inhibition by azidothymidine triphosphate.Biochemistry. 1994 Mar 1;33(8):2113-20. doi: 10.1021/bi00174a018. Biochemistry. 1994. PMID: 7509634
-
The observed inhibitory potency of 3'-azido-3'-deoxythymidine 5'-triphosphate for HIV-1 reverse transcriptase depends on the length of the poly(rA) region of the template.Biochemistry. 1992 Feb 11;31(5):1375-9. doi: 10.1021/bi00120a013. Biochemistry. 1992. PMID: 1371070
-
Mechanisms of resistance to nucleoside analogue inhibitors of HIV-1 reverse transcriptase.Virus Res. 2008 Jun;134(1-2):124-46. doi: 10.1016/j.virusres.2007.12.015. Epub 2008 Feb 12. Virus Res. 2008. PMID: 18272247 Review.
-
Mutational patterns in the HIV genome and cross-resistance following nucleoside and nucleotide analogue drug exposure.Antivir Ther. 2001;6 Suppl 3:25-44. Antivir Ther. 2001. PMID: 11678471 Review.
Cited by
-
The structure of HIV-1 reverse transcriptase complexed with an RNA pseudoknot inhibitor.EMBO J. 1998 Aug 3;17(15):4535-42. doi: 10.1093/emboj/17.15.4535. EMBO J. 1998. PMID: 9687519 Free PMC article.
-
Proteochemometric modeling of the susceptibility of mutated variants of the HIV-1 virus to reverse transcriptase inhibitors.PLoS One. 2010 Dec 15;5(12):e14353. doi: 10.1371/journal.pone.0014353. PLoS One. 2010. PMID: 21179544 Free PMC article.
-
The thiocarboxanilide nonnucleoside inhibitor UC781 restores antiviral activity of 3'-azido-3'-deoxythymidine (AZT) against AZT-resistant human immunodeficiency virus type 1.Antimicrob Agents Chemother. 1999 Feb;43(2):259-63. doi: 10.1128/AAC.43.2.259. Antimicrob Agents Chemother. 1999. PMID: 9925515 Free PMC article.
-
Bifunctional inhibition of human immunodeficiency virus type 1 reverse transcriptase: mechanism and proof-of-concept as a novel therapeutic design strategy.J Med Chem. 2013 May 23;56(10):3959-68. doi: 10.1021/jm400160s. Epub 2013 May 9. J Med Chem. 2013. PMID: 23659183 Free PMC article.
-
Bifunctional inhibition of HIV-1 reverse transcriptase: a first step in designing a bifunctional triphosphate.Bioorg Med Chem Lett. 2013 Mar 1;23(5):1511-8. doi: 10.1016/j.bmcl.2012.12.015. Epub 2012 Dec 20. Bioorg Med Chem Lett. 2013. PMID: 23380374 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources